Claim statement
Observational studies report associations between GLP-1 use and several substance-use outcomes, but they cannot establish causality or treatment effectiveness.
This claim needs careful boundaries around population, endpoint, mechanism, or source quality.
VV Claim Boundary Matrix v1.0
VV Claim Integrity Score
This score evaluates how cleanly the claim is bounded by evidence, source quality, applicability, risk handling, and graph support.
67/100
Partly Supported / Context-Dependent
- Evidence confidence
- 48/100
- Weight 22%
- Canonical editorial confidence in the reviewed evidence.
- Source quality
- 76/100
- Weight 16%
- Strength of source anchors for the claim lane.
- Applicability
- 45/100
- Weight 14%
- How well the evidence maps to the public claim.
- Boundary clarity
- 86/100
- Weight 16%
- Whether strong, weak, and falsifying versions are explicit.
- Overclaim containment
- 68/100
- Weight 12%
- Whether hype risk is controlled by the claim framing.
- Harm-risk handling
- 92/100
- Weight 10%
- Whether safety, regulatory, or caution context is visible.
- Graph support
- 66/100
- Weight 10%
- Depth of source, study, content, and related-claim links.
Partly Supported / Context-Dependent. The score is driven by applicability as the weakest dimension and remains bounded by evidence type, claim wording, source/study support, and visible limitations.
How the claim framework works ->Strongest version
Observational studies report associations between GLP-1 use and several substance-use outcomes, but they cannot establish causality or treatment effectiveness.
Weakest version
The evidence does not support turning this into a universal claim for every person or context.
What would change our mind
Larger, better-controlled, independently replicated evidence in the relevant population and outcome lane.
What supports this claim
Observational signal
Canonical sources and linked study records currently support this claim framing.
What weakens or limits this claim
Limitation
Confounding and coding limitations may influence observed associations.
Limitation
Randomized substance-specific outcomes are needed.
Limitation
Confounding and coding limitations may influence observed associations.
Limitation
Randomized substance-specific outcomes are needed.
Sources
- Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations - Molecular Psychiatry
- Semaglutide and opioid overdose risk in patients with type 2 diabetes and opioid use disorder - JAMA Network Open / PubMed Central
- GLP-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes - BMJ